Q-omics provides the consensus-scored TRIM61 profile across patient tissues and cancer cell-line models. TRIM61 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TRIM61 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TRIM61 RNA expression shows 16,431 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, THCA, and UVM as cancer lineages where TRIM61 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM61 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM61 survival associations across molecular data types. TRIM61 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM61 RNA expression–survival associations across cancer types. High TRIM61 expression shows unfavorable associations in LUSC, LGG, OV and UVM, but favorable associations in HNSC and ACC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for TRIM61 RNA expression.
This table summarizes TRIM61 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM61. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM61 shows lower tumor expression in THCA, LUSC, UCEC, LUAD and BRCA and higher tumor expression in HNSC. The THCA box plot shows higher TRIM61 RNA expression in normal versus tumor tissue (log2 FC = −1.301, t-test p < 0.001).
This table shows molecular features associated with TRIM61 in patient tissues and cancer cell lines. In patient samples, TRIM61 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM61 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
